Modulation of angiogenesis by A-beta peptides
AssigneeRoskamp Research LLC
InventorsDaniel Paris, Michael Mullan
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treating diseases and pathological conditions or processes mediated by undesired and/or uncontrolled angiogenesis (characterized as “angiogenic diseases”) by increasing the in vivo concentration of the Aβ peptide, or biologically active fragments or variants of the Aβ peptide, within a patient suffering from such diseases, conditions, or processes. The present invention also concerns diagnostic methods and kits for detection and measurement of anti-angiogenic Aβ peptide activity in biological fluids and tissues. Such diagnostic methods and kits can be utilized to screen compounds for potential therapeutic activity in the treatment of Alzheimer's disease.
Claims57
A method of inhibiting angiogenesis in a patient, said method comprising:
- increasing in vivo concentrations of an Aβ peptide within the patient to an angiogenesis inhibiting amount.
A method of preventing or alleviating the symptoms of an angiogenesis-mediated disease in a patient, said method comprising:
- increasing in vivo concentrations of an Aβ peptide within the patient to an angiogenesis inhibiting amount.
A method for identifying compounds that interfere with Aβ-induced angiogenesis inhibition, said method comprising the steps of:
- (a) contacting a first biological sample capable of undergoing angiogenesis with a test compound, a biologically active amount of an Aβ peptide, and an angiogenic agent;
- and
- (b) determining the extent of angiogenesis that occurs in the first biological sample.
A method for identifying compounds that interfere with Aβ-induced anti-tumor activity, said method comprising the steps of:
- (a) contacting a first tumor tissue with a test compound and a biologically active amount of an Aβ peptide;
- and
- (b) determining the extent of tumor growth that occurs in the first tumor tissue.
A kit for identifying compounds that interfere with Aβ-induced angiogenesis inhibition, wherein said kit comprises:
- (a) an Aβ peptide;
- (b) optionally, an angiogenic agent;
- and
- (c) optionally, a biological sample.
A kit for identifying compounds that interfere with Aβ-induced anti-tumor activity, wherein said kit comprises:
- (a) an Aβ peptide;
- and
- (b) optionally, a tumor tissue.
Dependencies are inferred from the claim text.